Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
World J Stem Cells. 2011 Oct 26;3(10):89-95. doi: 10.4252/wjsc.v3.i10.89.

Telomere dynamics in induced pluripotent stem cells: Potentials for human disease modeling.

Author information

  • Hinh Ly, Department of Veterinary and Biomedical Sciences, University of Minnesota, Twin Cities, MN 55108, United States.

Abstract

Recent advances in reprograming somatic cells from normal and diseased tissues into induced pluripotent stem cells (iPSCs) provide exciting possibilities for generating renewed tissues for disease modeling and therapy. However, questions remain on whether iPSCs still retain certain markers (e.g. aging) of the original somatic cells that could limit their replicative potential and utility. A reliable biological marker for measuring cellular aging is telomere length, which is maintained by a specialized form of cellular polymerase known as telomerase. Telomerase is composed of the cellular reverse transcriptase protein, its integral RNA component, and other cellular proteins (e.g. dyskerin). Mutations in any of these components of telomerase can lead to a severe form of marrow deficiency known as dyskeratosis congenita (DC). This review summarizes recent findings on the effect of cellular reprograming via iPS of normal or DC patient-derived tissues on telomerase function and consequently on telomere length maintenance and cellular aging. The potentials and challenges of using iPSCs in a clinical setting will also be discussed.

KEYWORDS:

Dyskeratosis congenita; Induced pluripotent stem cells; Marrow failure; Telomeres, Telomerase

PMID:
22110834
[PubMed]
PMCID:
PMC3220723
Free PMC Article

Images from this publication.See all images (1)Free text

Figure 1
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Baishideng Publishing Group Inc. Icon for PubMed Central
    Loading ...
    Write to the Help Desk